Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Condition:   HR+ HER2- Postmenopausal Advanced Breast CancerInterventions:   Drug: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant;   Drug: Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapySponsor:   Novartis PharmaceuticalsRecruiting - verified April 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2016 Category: Research Source Type: clinical trials

ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.
Condition:   Breast CancerIntervention:   Drug: EribulinSponsor:   Imperial College LondonRecruiting - verified January 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2016 Category: Research Source Type: clinical trials

Comparison of Efficacy and Tolerability of Fulvestrant+Placebo vs Fulvestrant+Palbociclib as First Line Therapy for Postmenopausal Women With HR+ Metastatic BC Treated With 5 Years of Hormonal Therapy Remaining Disease Free More Than 12 Months After Completion or Have de Novo Metastatic Disease
Condition:   Breast NeoplasmsInterventions:   Drug: PD-0332991 (Palbociclib);   Drug: Fulvestrant;   Drug: PlaceboSponsors:   Spanish Breast Cancer Research Group;   AstraZenecaNot yet recruiting - verified February 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2016 Category: Research Source Type: clinical trials

Comparison of Efficacy and Tolerability of Fulvestrant+Placebo vs Fulvestrant+Palbociclib as First Line Therapy for Postmenopausal Women With HR+ Metastatic BC Treated With 5 Years of Hormonal Therapy Remaining Disease Free More Than 12 Months After Completion or Have de Novo Metastatic Disease
Condition:   Breast NeoplasmsInterventions:   Drug: PD-0332991 (Palbociclib);   Drug: Fulvestrant;   Drug: PlaceboSponsors:   Spanish Breast Cancer Research Group;   AstraZenecaRecruiting - verified March 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2016 Category: Research Source Type: clinical trials

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
Condition:   Prostatic NeoplasmsInterventions:   Drug: Doxorubicin;   Drug: Ketoconazole;   Drug: Docetaxel;   Drug: Estramustine;   Drug: DegarelixSponsor:   The University of Texas Health Science Center, HoustonNot yet recruiting - verified September 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2015 Category: Research Source Type: clinical trials

Effect of the Pelvic Floor Training in Postmenopausal Women With or Without Hormonal Therapy
Conditions:   Weak; Pelvic Floor;   Weak; Muscle;   Urinary IncontinenceIntervention:   Behavioral: pelvic floor muscle trainingSponsor:   University of Sao PauloNot yet recruiting - verified September 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2015 Category: Research Source Type: clinical trials